uPath PD-L1 (SP263) image analysis, NSCLC (CE-IVD)

Ready-to-use, fast, consistent and automated algorithm for clinical decision support


uPath image analysis algorithms

An intelligent and insightful digital pathology solution requires image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images. The algorithm is indicated for use as an aid in identifying patients for treatment with therapies with the ≥ 50% PD-L1 TC positivity cutoff in accordance with the approved therapeutic product labeling.


uPath PD-L1 (SP263) image analysis, NSCLC features
  • Pathologist trained artificial intelligence: Resulting in objective and reproducible scoring of VENTANA DP 200 slide images stained with the VENTANA PD-L1 (SP263) Assay
  • Integrated into the clinical uPath software: Seamless viewing, aligning and syncing functionality, sharing capabilities, and reporting
  • Whole slide analysis (WSA): Automated pre-computing of the slide image prior to pathologist assessment, providing fast results for user-defined regions of interest (ROI)
  • One-click automated scoring: Quickly calculates PD-L1 (SP263) tumor cell staining positivity, aiding potential treatment strategies at the ≥ 50% cutoff
  • Clear visual overlay: Highlighting positively and negatively stained tumor cells for easy reference

Integrated and ready-to-use

Validated on the VENTANA PD-L1 (SP263) Assay, for use within Roche uPath enterprise software.

Quick and automated

Pathologist trained artificial intelligence algorithm for one-click image analysis.

Accurate, consistent and confident

Actionable assessment of scanned slide images that are objective and reproducible, aiding in informing on potential treatment strategies.

Reference: uPath PD-L1 (SP263) image analysis for Non-Small Cell Lung Cancer Algorithm Guide   

uPath PD-L1 (SP263) image analysis, NSCLC (CE-IVD) is not yet commercially avaiable in Sweden